- Welcome, Logout
Register for FREE
Register for FREE

Thank you for registering.

We sent an email to:

Please click on the link inside the email to complete your registration
Please register to gain free access to WSJ tools.

An account already exists for the email address entered.

Forgot your username or password?

This service is temporary unavailable due to system maintenance. Please try again later.

The username entered is already associated with
another account. Please enter a different username

The email address you have entered is already in use.
Please re-enter the email address.

First Name

Last Name

Email Address

Create a User Name

Create a Password

Confirm Password

Send me information about more WSJ features

Create a profile for me in the Journal Community
Why Register?

Privacy Policy | Terms & Conditions

As a registered user of The Wall Street Journal Online, you will be able to:

Setup and manage your portfolio

Personalize your own news page

Receive and manage newsletters
Log In

Log In

User Name

Password

Log in

Remember me Forgot your password?

Pricey Drugs Put Squeeze on Doctors

Article
Comments

SAN FRANCISCO -- Long a burden for patients, hyperexpensive cancer drugs are causing economic havoc for another constituency in U.S. health care: doctors.

American doctors rarely used to let costs factor into their treatment decisions. But rising prices -- some cancer drugs now cost more than $100,000 a year -- are dramatically changing that ethos in the field of oncology. Money issues are now disrupting relationships with patients, causing doctors to go into debt and threatening to interfere with treatment options.

Unlike most physicians, who write patients prescriptions that they can fill at a pharmacy, oncologists must buy many drugs ...